Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 41 of 5804
-
Immunotherapy drug could boost cervical cancer treatment
Disease control Recruiting nowThis study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).
Phase: PHASE3 • Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Promising Three-Drug cocktail targets tough leukemia mutation
Disease control Recruiting nowVenetoclax can bind to the BCL-2 protein, thereby initiating the apoptosis program and exerting anti-AML effects. The induction regimen combining venetoclax with hypomethylating agents (HMA) significantly improves the remission rate (over 60%) in elderly unfit AML patients and ma…
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New TB drug could cut treatment time by two months
Disease control Recruiting nowThis study aims to assess quabodepistat-based treatment regimens for RR/MDR-TB. The study will enroll adults and adolescents with rifampicin-resistant or multidrug-resistant pulmonary TB. The main goal is to see if a new drug called quabodepistat, when combined with other TB drug…
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Gene editing shot aims to tame deadly fat levels in rare disease
Disease control Recruiting nowThis is an open-label, single-arm, dose-escalation Phase I clinical trial to evaluate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of CS-121, an in vivo base editing therapy delivered by lipid nanoparticles targeting APOC3, in adult participants (18-…
Phase: EARLY_PHASE1 • Sponsor: CorrectSequence Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can these diabetes drugs stop liver failure? major trial launches
Disease control Recruiting nowThe main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD). The study will enroll adults who have MASLD…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Simple brain scan could open lifesaving stroke treatment to millions worldwide
Disease control Recruiting nowThe DONE SYMPLE Investigator-initiated phase III prospective, randomized, open-label, blinded endpoint-controlled clinical trial. This clinical trial is a global clinical study testing whether a procedure called endovascular therapy, which removes blood clots from blocked brain …
Phase: NA • Sponsor: Santiago Ortega Gutierrez • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New targeted combo aims to outsmart KRAS lung cancer
Disease control Recruiting nowResearchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New cell therapy offers hope for tough blood cancers
Disease control Recruiting nowThe goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age of 12 will be eligible to participate. Participants will receive one infusion of…
Phase: PHASE1, PHASE2 • Sponsor: BIOHENG THERAPEUTICS US LLC • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Chemo-Free hope: new drug combo may spare thousands from toxic treatment
Disease control Not yet recruitingThe investigators designed a phase III clinical trial involving hormone receptor-positive and HER2-positive stage I breast cancer patients. This trial aims to evaluate the efficacy and safety of a treatment regimen combining CDK4/6 inhibitors, endocrine therapy, and anti-HER2 the…
Phase: PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New hope for Drug-Resistant TB: shorter, safer treatment on the horizon?
Disease control Recruiting nowPRISM-TB is an international, seamless, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, multi-arm multi-stage (MAMS), noninferiority Phase 2/3 clinical trial for fluoroquinolone-susceptible multidrug-resistant/rifampin-resist…
Phase: PHASE2, PHASE3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Mind-Reading chip: neuralink Robot-Implants brain device for speech
Disease control Recruiting nowThe VOICE Study is an early feasibility study to evaluate the initial clinical safety and efficacy of the N1 and R1 Systems device design concept in providing an ability to communicate. The Neuralink N1 Implant is intended to provide the ability to communicate to individuals with…
Phase: NA • Sponsor: Neuralink Corp • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New CAR-T therapy aims to wipe out myeloma cells
Disease control Recruiting nowThe purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative adm…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
HPV vaccine trial aims to protect women with HIV from cervical cancer
⭐️ VACCINE ⭐️ OngoingHuman papillomavirus (HPV) infection is the most common viral infection of the reproductive tract. Up to 80%of the sexually active females and men will be infected with HPV at some point in their lives and some may be repeatedly infected. The main burden of HPV-related disease is…
Phase: PHASE3 • Sponsor: Serum Institute of India Pvt. Ltd. • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 01, 2026 00:00 UTC
-
New injection method aims to stop bladder cancer from returning
Disease control Not yet recruitingBladder cancer is the most common malignant tumor of the urinary system in China, and its incidence has been increasing year by year. It is classified into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). NMIBC accounts for 75% of newly diagno…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai University of Traditional Chinese Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug combo aims to slow ALS in landmark trial
Disease control Recruiting nowThe ALSTARS trial will be conducted across 20-25 sites in the US and Canada, and will evaluate the safety and efficacy of an investigational treatment called COYA 302 for adults with Amyotrophic Lateral Sclerosis (ALS). COYA 302 is an investigational and proprietary biologic com…
Phase: PHASE2 • Sponsor: Coya Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New alpha therapy shows promise for deadly brain cancer
Disease control Recruiting nowBrain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups. The incidence of malignant gliomas is approximately 0.5-2 per 100,000 people annual…
Phase: NA • Sponsor: Medical University of Warsaw • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Double stem cell transplant could be Game-Changer for rare blood disorder
Disease control Recruiting nowAplastic anemia (AA) is a bone marrow failure disorder characterized by pancytopenia and hypoplastic bone marrow caused by the decrease of hematopoietic stem cells. The pathogenesis of AA is complex and involves an abnormal hematopoietic microenvironment, hematopoietic stem cell/…
Phase: NA • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Can a 45-Minute chat save lives? huge swedish study aims to find out
Prevention Recruiting nowSuicide is one of the leading causes of premature death and a prioritized public health concern. Safety Planning Intervention (SPI) is a method with strong international research support for reducing suicidal behaviour by enhancing individuals' strategies for crisis management a…
Phase: NA • Sponsor: Region Skane • Aim: Prevention
Last updated Jun 27, 2026 11:01 UTC
-
New hope for endometrial cancer: targeted drug trial launches
Disease control Recruiting nowThis study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Could stem cells heal a scarred uterus and restore fertility?
Disease control Not yet recruitingThe goal of this clinical trial is to test a new approach: delivering human bone marrow mesenchymal stem cells (hBMSCs) via the uterine artery to treat infertility caused by severe intrauterine adhesions (IUA). This method may help stem cells better reach the deep layer of the en…
Phase: NA • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 26, 2026 18:28 UTC